secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001285550-23-000096
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q2 revenue record $6.0M (+14% YoY); biologics growth 40%; reaffirms FY guide $25-27M
--------------------------------------------------------------------------------

- Record Q2 revenue $6.0M, up 14% YoY; biologics & drug delivery revenue $3.4M (+40%).
- Gross margin fell to 53% from 63% due to lower-margin preclinical services and facility transition costs.
- Operating expenses rose to $10.3M from $7.5M on higher headcount, stock comp, and product development.
- Cash & equivalents $26.5M at June 30, down from $37.5M at Dec 2022; operating cash burn $10.8M.
- Reaffirmed FY2023 revenue guidance $25-27M; CEO outlines five key milestones for H2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/0001285550-23-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/clpt-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001285550-23-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer